CerK was also associated with a poor prognosis in breast cancer patients [34], and endocrine therapy-resistant breast cancer cells were more sensitive to CerK inhibition than therapy-sensitive breast cancer cells [35]. This evidence concerns the gene CERK and breast carcinoma.